Data from DELIVER and ACHIEVE Clinicals Trial to be Presented -- Presentation on ACHIEVE Trial in DM1 and Company Symposium to Feature Data on ...

Two months after Allogene abandoned plans for its CAR-T in leukemia, analysts have suggested that fresh phase 1 data in ...

Biohaven boasts a robust pipeline with late-stage molecules, but a Hold rating reflects its high market cap and uncertain ...

Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with ...

All treated AML patients in both the original and expansion cohorts through January 17, 2025 remain in complete remission. The original cohort of AML patients has reached a median CR of 23.3 months, ...

SAB BIO, (“SAB BIO”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human ...

Without sacrificing on the robust science of R&D, teams were able to accelerate overall development schedules by removing lags in clinical trial phase timelines. Conversely, there are challenges ...

As Việt Nam embarks on a new development phase, UNDP looks forward to deepening this partnership and addressing the country’s most pressing challenges together. In what ways can UNDP support Việt Nam ...

However, most software development is not static. This dilemma, among others, has caused a new branch of blockchain-oriented software engineering. This paper emphasizes the importance of the early ...